Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference
On October 3, 2022, Reunion Neuroscience (TSX: REUN, Nasdaq: REUN) announced its participation in the Cantor Neurology & Psychiatry Conference scheduled for October 6-7, 2022, at the Ritz Carlton, San Francisco. The management team will present on the panel titled “Tripping Our Way to a New Treatment Paradigm for Psychiatric Disorders” on October 6 at 12:10 PM PT. Additionally, they will conduct one-on-one meetings with institutional investors. Reunion focuses on the development of innovative psychedelic therapies, including its lead asset, RE-104, aimed at treating post-partum and treatment-resistant depression.
- None.
- None.
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will participate in the Cantor Neurology & Psychiatry Conference taking place on October 6-7, 2022 at the Ritz Carlton, San Francisco.
The Reunion management team will participate in the panel presentation, “Tripping Our Way to a New Treatment Paradigm for Psychiatric Disorders: Intermittent Therapy vs Chronic Treatment,” on Thursday, October 6 at 12:10-1:10 PM Pacific Time / 3:10-4:10 PM Eastern Time in Track 1.
Management will also take part in one-on-one meetings over the duration of the conference. Institutional investors interested in scheduling a meeting with Reunion’s management team, or for more information on the conference, please contact KCSA Strategic Communications at Reunion@kcsa.com.
About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
Learn more at https://investors.reunionneuro.com, and https://www.reunionneuro.com.
Follow us on Twitter and Instagram: @reunionneuro.
To be added to the Reunion Neuroscience email list, please email Reunion@kcsa.com with “REUN” in the subject line.
Cautionary Note Regarding Forward-Looking Information
This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
CONTACTS:
Reunion Neuroscience:
Greg Mayes
President & CEO
(215) 696-9659
gmayes@reunionneuro.com
Media contacts:
Caitlin Kasunich
KCSA Strategic Communications
(212) 896-1241
reunion@kcsa.com
Investor contacts:
Phil Carlson / Sophia Bashford
KCSA Strategic Communications
(646) 573-0776 / (929) 246-7307
reunion@kcsa.com
SOURCE Reunion Neuroscience Inc.
FAQ
When is Reunion Neuroscience participating in the Cantor Neurology & Psychiatry Conference?
What is the focus of Reunion Neuroscience's panel presentation at the conference?
Where is the Cantor Neurology & Psychiatry Conference being held?
What therapeutic solutions is Reunion Neuroscience developing?
How can investors schedule a meeting with Reunion Neuroscience's management team?
